Trial Profile
IMATINIB MESYLATE IN ADVANCED LOW GRADE SOLID TUMORS EXPRESSING IMATINIB MESYLATE TARGETS.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Carcinoma; Haemangioendothelioma; Solid tumours
- Focus Therapeutic Use
- 29 Jul 2011 New trial record